RAP 0.00% 20.5¢ resapp health limited

Ann: Phenix and ResApp Sign Software Licensing Agreement, page-2

  1. 5,592 Posts.
    lightbulb Created with Sketch. 359
    The two-year, non-exclusive commercial software licensing agreement allows Phenix to use ResAppDx-EU in their telehealth smartphone app within Australia from 1 July 2020. The per test license fee received by ResApp is in the previously targeted range of $5 to $10. The licence may be extended beyond the initial two-year term by mutual agreement and either party may terminate the licence by providing 60 days written notice.

    NICE
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.